We are committed to developing our off-the-shelf, allogeneic platform and welcome collaboration and licensing opportunities in the following areas:
If you would like to discuss partnering with Atara Biotherapeutics, please contact firstname.lastname@example.org.
We entered into an exclusive option agreement with Memorial Sloan Kettering Cancer Center (MSK) for the development and commercialization of allogeneic T-cell therapies developed in the lab of Dr. Richard O’Reilly for the treatment of certain cancers and persistent viral infections. Under the terms of the agreement, we had the option to acquire a worldwide license to three clinical stage T-cell therapies consisting of T‑Cells activated against Epstein Barr Virus (EBV) (Phase 2); T‑Cells activated against cytomegalovirus (CMV) (Phase 2); and T‑Cells activated against Wilms Tumor 1 (WT1) (Phase 1).
We exercised the option and entered into a license agreement with MSK. Under the terms of the license agreement, MSK granted us a worldwide, exclusive license under certain patent rights, know-how and a library of T‑Cells and cell lines, to research, develop, manufacture and commercialize T-cell products specific to CMV, EBV, and WT1 that comprise or are based on or made using such licensed rights.
Atara expanded our collaboration with Memorial Sloan Kettering Cancer Center (MSK) to develop the next generation of genetically engineered chimeric antigen receptor T-cell (CAR T) immunotherapies. We gained access to several of MSK’s innovative enabling technologies, including a novel co-stimulatory domain that Atara believes has physiologic T-cell activation properties, as well as methods for designing CAR T immunotherapies. Atara has entered into an exclusive research collaboration for multiple targets with Michel Sadelain, M.D., Ph.D., Director, Center for Cell Engineering at MSK, to employ next-generation technologies in developing novel CAR T immunotherapies with applications in oncology, autoimmune and infectious diseases.
We exclusively licensed worldwide rights to a mesothelin-targeted chimeric antigen receptor T-cell (CAR T) immunotherapy for solid tumors developed in the lab of Dr. Prasad Adusumilli. The most advanced program in Atara’s CAR T collaboration with MSK is focused on the development of a next-generation, mesothelin-targeted CAR T using novel 1XX CAR signaling domain and PD-1 dominant negative receptor (DNR) checkpoint inhibition technologies for patients with mesothelin-associated solid tumors.
We obtained an exclusive, worldwide license to develop and commercialize allogeneic, or “off-the-shelf”, cytotoxic T-lymphocytes (CTLs) directed against multiple epitopes of the Epstein-Barr virus (EBVpoly) and multiple epitopes of the cytomegalovirus (CMVpoly) utilizing technology developed by Dr. Rajiv Khanna at QIMR Berghofer. The QIMR Berghofer technology complements our ongoing CTL development efforts by selectively targeting certain epitopes and antigens. Initial applications for which the technology may be appropriate include the treatment of certain cancers such as gastric cancer, nasopharyngeal carcinoma (NPC) and glioblastoma multiforme (GBM), and certain autoimmune disorders such as multiple sclerosis (MS).
We entered into a strategic collaboration with Moffitt Cancer Center to develop multi targeted chimeric antigen receptor T-cell (CAR T) immunotherapies for patients with AML and B cell malignancies being developed by Dr. Marco Davila. As part of the collaboration, Atara gained access to novel CAR T targeting and co stimulation domains designed to improve T-cell proliferation and enhance persistence. This agreement furthers the Company’s strategy to develop next-generation engineered CAR T immunotherapies across multiple therapeutic areas and leverage the Company’s off-the-shelf, allogeneic T-cell immunotherapy platform.
Next-Generation CAR T technologies will seek to overcome therapeutic challenges in various medical areas.Next-Generation CAR T